RxDoctor Payments Data

Sarah Rudder

Family · Calhoun Falls, SCNPI 1437780053

Payments from drug & device makers

$581in general payments, 2019–2025

Across 23 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$152
  • Sanofi-aventis U.S. LLC$135
  • AbbVie$117
  • AstraZeneca$53
  • Dexcom, Inc.$26
  • Organon$23
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581 in reported general payments places this provider in the 55th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,819
Medicare patients
56
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate109$124,849
OzempicSemaglutide76$115,202
EliquisApixaban78$79,876
JardianceEmpagliflozin70$78,193
MounjaroTirzepatide30$49,575
RybelsusSemaglutide19$40,399
XifaxanRifaximin12$39,412
FarxigaDapagliflozin Propanediol26$33,872
XareltoRivaroxaban22$25,596
Tresiba Flextouch U-200Insulin Degludec12$22,222
TradjentaLinagliptin26$16,575
Spiriva HandihalerTiotropium Bromide17$16,153
Janumet XrSitagliptin Phos/Metformin Hcl11$15,660
LinzessLinaclotide19$13,433
Breo ElliptaFluticasone/Vilanterol24$10,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$152$155,60195 claims
Lilly USA, LLCMounjaro$23$49,57530 claims
AstraZenecaFarxiga, Symbicort$53$38,82049 claims
AbbVieLinzess$117$13,43319 claims
GSKBreo Ellipta$21$10,06724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,248 family providers in South Carolina.

Other family in Calhoun Falls

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →